Study of frail older adult patients with myeloma showed reduced disease progression and death with a regimen reducing dexamethasone exposure.

Emma Reeve, the chair of Editas’ board, is also resigning, to be replaced by Jessica Hopfield, Ph.D., the company explained ...

For patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia (ALL) with an average or high risk for ...

Prelude Therapeutics (Nasdaq: PRLD) presented encouraging interim results from its Phase 1 trial of PRT2527, an ...

Long-term exposure to air pollution poses an increased risk of blood clots in deep veins, which can result in serious ...

STAT reporters discuss why drugmakers have not lobbied against RFK Jr.'s nomination to lead HHS and the struggles around ...

A pair of studies presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition highlight continuing ...

In a presentation at the recent American Society of Hematology meeting in San Diego, Kite Pharma Inc. reported preclinical data for KITE-753, an autologous rapid manufactured anti-CD19/CD20 CAR T-cell ...

Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...

Research at the annual meeting of the American Society of Hematology evaluated patient and caregiver perspectives on gene ...

I just returned from San Diego and the annual meeting of the American Society of Hematology, where Arcellx won the battle of ...

A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...